Search Results
Dec 05, 2025, 15:11 ET AV-Comparatives triunfa en "Tiroler Innovationspreis 2025"
IoTCon su entrada, AV-Comparatives presentó la primera plataforma escalable de pruebas y certificación del IoT de Europa. Junto con académicos de MCI Innsbruck, desarrollaron un sistema robusto y automatizado diseñado para evaluar la ciberresiliencia de los dispositivos conectados, de conformidad con
More news about: AV-Comparatives
Dec 05, 2025, 11:42 ET AV‑Comparatives triumphs at 2025 "Tiroler Innovationspreis 2025"
standardsWith its entry AV‑Comparatives presented Europe's first scalable IoT‑ testing and certification platform. Together with scholars from MCI Innsbruck, they developed a robust, automated system designed to evaluate the cyber‑resilience of connected devices, also in accordance with forthcoming
More news about: AV-Comparatives
Dec 05, 2025, 11:32 ET AV‑Comparatives triumphs at 2025 "Tiroler Innovationspreis 2025"
standardsWith its entry AV‑Comparatives presented Europe's first scalable IoT‑ testing and certification platform. Together with scholars from MCI Innsbruck, they developed a robust, automated system designed to evaluate the cyber‑resilience of connected devices, also in accordance with forthcoming
More news about: AV-Comparatives
Dec 04, 2025, 02:18 ET New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment
the time to progression from MCI to mild AD was 13.2 years with continued Leqembi treatment to the onset of moderate AD, suggesting a time savings of 6.0 years.Time Savings from MCI due to AD to Moderate ADThe time to progression from MCI due to AD to moderate AD was
More news about: BioArctic
Dec 04, 2025, 02:13 ET New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment
the time to progression from MCI to mild AD was 13.2 years with continued Leqembi treatment to the onset of moderate AD, suggesting a time savings of 6.0 years.Time Savings from MCI due to AD to Moderate ADThe time to progression from MCI due to AD to moderate AD was
More news about: BioArctic
Dec 03, 2025, 22:28 ET Mazda informa resultados de ventas de noviembre
1990, con 32.909 vehículos vendidos.Las mejores ventas de noviembre del CX-50, con 11.583 vehículos vendidos.Mazda Canada, Inc. (MCI) registró ventas de 5.982 vehículos en noviembre, lo que supone un aumento del 5 % en comparación con el año pasado. Las ventas acumuladas en lo que
More news about: Mazda North American Operations
Dec 03, 2025, 18:10 ET Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
time to progression from MCI to mild AD was 13.2 years with continued LEQEMBI treatment to the onset of moderate AD, suggesting a time savings of 6.0 years.Time Savings from MCI due to AD to Moderate ADThe time to progression from MCI due to AD to moderate AD
More news about: Eisai Inc.
Dec 02, 2025, 16:40 ET New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
PET.5INDICATIONLEQEMBI® is indicated for the treatment of Alzheimer's disease (AD). Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.IMPORTANT SAFETY INFORMATION
More news about: Eisai Inc.
Dec 02, 2025, 10:49 ET Mazda Reports November Sales Results
November since 1990 with 32,909 vehicles sold.Best-ever November sales of CX-50 with 11,583 vehicles sold.Mazda Canada, Inc., (MCI) reported November sales of 5,982 vehicles, an increase of 5 percent compared to last year. Year-to-date sales totaled 76,814 vehicles sold; an increase
More news about: Mazda North American Operations
Nov 28, 2025, 09:07 ET Market Force Information® Parent MCI Taps FEMA/DHS Veteran Executive Mark Misczak as President; Spins Out Tier-5 AiCX.com Division
enhancing how we deliver for our clients and partners. MCI will split into MCI BPO, which will be a roughly ~$200M ARR division in 2026 with tech-enabled human capital, and our new spinout MCI
More news about: Market Force Information
Nov 25, 2025, 07:30 ET Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
after the FDA granted Fast Track Status. LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). Upon acceptance of the sBLA, the FDA will set a Prescription Drug User Fee
More news about: Eisai Inc.
Nov 24, 2025, 12:39 ET Alzheimer's Association 針對口服塞瑪格魯肽 (Semaglutide) 第三期臨床試驗頂線數據發佈之聲明
多元化與擴展之勢。」該公司表示，「儘管兩項試驗中使用司美格魯肽治療均改善了阿茲海默症相關生物標記物，但這並未轉化為延緩疾病進展的效果。」Evoke 和 evoke+ 試驗是大規模的長期國際臨床試驗。研究共納入超過 3,800 名年齡介於 55 至 85 歲、經診斷為輕度認知障礙 (MCI) 或因阿茲海默症導致輕度失智症（即阿茲海默症第 3 期與第 4 期）的受試者。Alzheimer's Association 科學總監兼醫療事務負責人
More news about: Alzheimer's Association
Nov 24, 2025, 11:57 ET Alzheimer's Association Statement on Oral Semaglutide Phase 3 Topline Data Release
internacionais de grande escala e longo prazo. Mais de 3.800 pessoas com idades entre 55 e 85 anos diagnosticadas com comprometimento cognitivo leve (MCI) ou demência leve devido à doença de Alzheimer (referidos como estágios 3 e 4 da doença de Alzheimer) foram inscritos."Esses resultados nos ajudarão
More news about: Alzheimer's Association
Nov 24, 2025, 11:56 ET Stellungnahme der Alzheimer's Association zur Veröffentlichung der ersten Phase-3-Daten von Semaglutid
langfristige internationale klinische Studien. Mehr als 3 800 Personen im Alter von 55 bis 85 Jahren, bei denen eine leichte kognitive Beeinträchtigung (MCI) oder eine leichte Demenz aufgrund der Alzheimer-Krankheit diagnostiziert wurde (als Stadium 3 und 4 der Alzheimer-Krankheit bezeichnet), wurden in die
More news about: Alzheimer's Association
Nov 24, 2025, 11:56 ET Déclaration de l'Alzheimer's Association sur la publication des résultats préliminaires de la phase 3 du Semaglutide oral
internationaux à grande échelle et à long terme. Plus de 3 800 personnes âgées de 55 à 85 ans, diagnostiquées avec une déficience cognitive légère (MCI) ou une démence légère due à la maladie d'Alzheimer (appelée stade 3 et 4 de la maladie d'Alzheimer), ont été enrôlées.« Ces résultats nous aideront
More news about: Alzheimer's Association
Nov 24, 2025, 10:00 ET Alzheimer's Association Statement on Oral Semaglutide Phase 3 Topline Data Release
evoke+ trials were large-scale, long-term international clinical trials. More than 3,800 people ages 55-85 diagnosed with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease, (referred to as stage 3 and 4 of Alzheimer's disease), were enrolled."These results will help us
More news about: Alzheimer's Association
Nov 24, 2025, 09:36 ET Alzheimer's Association Statement on Oral Semaglutide Phase 3 Topline Data Release
evoke+ trials were large-scale, long-term international clinical trials. More than 3,800 people ages 55-85 diagnosed with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease, (referred to as stage 3 and 4 of Alzheimer's disease), were enrolled."These results will help us
More news about: Alzheimer's Association
Nov 18, 2025, 10:00 ET Linus Health Highlights AI-Enabled Solutions Advancing Early Alzheimer's Detection and Clinical Trial Readiness at CTAD 2025
clinical workflows, this work underscores the potential of scalable, AI-enabled tools to support timely diagnosis and intervention for people at risk of MCI and dementia due to AD. Linus Health will host meetings at CTAD with life sciences partners throughout the conference to discuss
More news about: Linus Health
Nov 13, 2025, 18:51 ET Leqembi® approved for IV maintenance treatment in the United Kingdom
Agency (MHRA) in the United Kingdom. In August 2024, Leqembi was approved for the treatment of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in adult patients that are apolipoprotein E ε4 (ApoE ε4)[1] heterozygotes or non-carriers
More news about: BioArctic
Nov 13, 2025, 18:50 ET Leqembi® approved for IV maintenance treatment in the United Kingdom
Agency (MHRA) in the United Kingdom. In August 2024, Leqembi was approved for the treatment of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in adult patients that are apolipoprotein E ε4 (ApoE ε4)[1] heterozygotes or non-carriers
More news about: BioArctic
Nov 05, 2025, 07:00 ET Midwest Cardiovascular Institute and Basata Partner to Modernize Cardiac Care with Voice AI
faster and more accessible. MCI is a model for modern cardiovascular care." Looking ahead, MCI and Basata plan to expand the partnership beyond the call center to additional departments and workflows across the organization. This phased approach will allow MCI to systematically enhance
More news about: Basata & Midwest Cardiovascular Institute
Nov 04, 2025, 20:29 ET Mazda presenta los resultados de ventas de octubre
Mejores ventas de la historia del CX-50 en octubre, con 8,351 vehículos vendidos. Mazda Canada, Inc. (MCI) ha registrado ventas en octubre de 6,815 vehículos, lo que supone un incremento del 0.1% respecto al año pasado. Las ventas en lo que va de año ascienden
More news about: Mazda North American Operations
Nov 04, 2025, 08:34 ET Upgraded Points Study Finds the Best and Worst Airports for a Boozy Layover
passengers, which is 76% more than the average airport. Kansas City International Airport (MCI): Its alcohol-serving venues earned the highest average Google rating in the study (4.16 out of 5 stars), and it leads the study in bar accessibility
More news about: Upgraded Points
Nov 03, 2025, 10:22 ET Mazda Reports October Sales Results
Second best October sales of CX-50 with 8,351 vehicles sold. Mazda Canada, Inc., (MCI) reported October sales of 6,815 vehicles, an increase of .1 percent compared to last year. Year-to-date sales totaled 70,832 vehicles sold; an increase
More news about: Mazda North American Operations
Nov 03, 2025, 01:30 ET Arctic Therapeutics Receives EMA Approval for Phase IIa Study of AT-001 in Alzheimer's Disease
has initiated a Phase IIa clinical trial to evaluate the safety and biomarker-based efficacy of AT-001 in individuals with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (AD). The multicentre, randomized, double-blind, placebo-controlled, dose-escalation study will assess the
More news about: Arctic Therapeutics